Table I.
Effect of vorinostat on the expression of CD146 in clinical tumor samples.
| Time course, h | ||||||
|---|---|---|---|---|---|---|
| Patients | Clinical diagnosis | Classification | 0 | 3 | 6 | 12 |
| Patient 1 | Ovarian cancer | Serous | 1 | 76.40±7.25 | 16.33±2.78 | 15.97±1.64 |
| Patient 2 | Ovarian cancer | Mucinous | 1 | 77.13±6.65 | 14.02±2.45 | 13.23±1.76 |
| Patient 3 | Ovarian cancer | Serous | 1 | 80.52±7.81 | 18.59±2.97 | 17.13±2.35 |
| Patient 4 | Ovarian cancer | Serous | 1 | 54.21±4.36 | 15.47±3.75 | 11.24±1.88 |
| Patient 5 | Ovarian cancer | Mucinous | 1 | 73.26±6.82 | 21.67±1.98 | 20.57±1.18 |
| Patient 6 | Ovarian cancer | Serous | 1 | 103.42±8.93 | 46.15±2.60 | 37.22±2.71 |
| Patient 7 | Ovarian cancer | Serous | 1 | 66.57±5.33 | 50.14±3.08 | 26.89±3.43 |
| Patient 8 | Ovarian cancer | Serous | 1 | 90.36±7.47 | 65.11±4.23 | 30.78±3.59 |
Data are expressed as fold increase (mean ± standard error) of CD146 messenger RNA from vorinostat-treated ovarian cancer cells relative to that from medium-treated cells. Each data point was obtained from ≥3 independent experiments. CD146, cluster of differentiation 146.